KINETA INC. news, videos and press releases
For more news please use our advanced search feature.
KINETA INC. - More news...
KINETA INC. - More news...
- Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
- Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
- Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
- Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
- Kineta, Inc Transitioning from Nasdaq to OTC Markets
- Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
- Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
- Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
- Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
- Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
- KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
- Kineta Announces Restructuring and Exploration of Strategic Alternatives
- Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
- Kineta to Present at Upcoming Investor Conferences
- Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
- Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
- Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
- Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
- Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
- Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
- Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
- Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023
- Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
- Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
- Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
